Outsourcing-Pharma presents its round-up of the latest career news in the pharmaceutical biz, including new appointments at inVentiv, BioClinica and Novella.
Novella Clinical Resourcing (NCR) has drafted in Rob Stallings as executive VP.
Formerly an executive VP for ClinForce, he joins the firm – a division of Novella Clinical – as it prepares to expand its services. The firm provides solutions for companies looking to hire clinical research professionals.
President and CEO of NCR Richard Staub said:"Rob's wealth of experience will benefit our clients and drive NCR to become an even more powerful force in the clinical resourcing arena.”
Stallings replaces Jean Hendrickson, who will now develop a global physician network of medical advisors and consultants to support Novella’s portfolio of oncology and medical device programs.
inVentiv Health has named Mark Archer senior VP of European operations and development for its commercial sector.
Previously, Archer was VP of global business development for Quintiles.
A spokesperson for the firm said of his new appointment: “Working closely with inVentiv, Archer will lead the company’s efforts to broaden its commercial operations in Europe and identify and support new business opportunities in the region.”
Clinical trial management bod BioClinica has promoted two of its staff to executive level roles.
Dawn Flitcraft will become the new senior VP of client services for the firm’s imaging solutions biz. She previously oversaw the project management and imaging core lab departments of the division.
CEO Mark Weinstein said: “Dawn’s expertise and management skills have helped BioClinica to become the preferred choice for imaging core lab services, worldwide.”
Meanwhile Garry Johnson will become executive VP. He first joined the firm with the sole aim of building up its tech expertise, and later led the firm’s overall IT-based strategies.
Weinstein added: “Technology is a key part of our success, and we are pleased that Garry will pilot our technology operations as we grow operations along with our suite of industry-leading applications.”
Catalent has appointed Jeremie Trochu as VP of commercial excellence.
He joins the team from General Electric’s healthcare division where he was general manager of sales resource optimisation.
Trochu will now take responsibility for the company’s entire sales force.
“As Catalent continues to grow with investments in acquisitions, drug delivery technologies, new capabilities and site expansions, I am excited to have Jeremie join the Catalent team to help enhance our sales capabilities across all offerings,” said Will Downie, senior VP of global sales and marketing.
Kuljit Bhatia has become the new VP of R&D (research and development) at DPT Laboratories.
Prior to joining the contract development and manufacturing organization (CDMO), Bhatia was VP of R&D and technical operations at Fougera Pharmaceuticals.
In his new role he will take charge of the firm’s research teams and its R&D Center of Excellence in San Antonio.
Oh his new role, he said: "I am excited to be a part of DPT, which has established a reputation as the leader in semi-solid and liquid development. I believe my experience in pharmaceutical drug development will be a good strategic fit with the strong team of scientists DPT has in place.”
Oncology-focused CRO (contract research organisation) Preclinical Oncology Services Limited, or PRECOS, has hired Martin Page as scientific consultant.
Before joining PRECOS, Page was VP and head of global oncology research for J&J’S activities in Belgium and the US. He has also been at the forefront of several discovery teams looking at small molecule and MAb anti-cancer agents.
Page said: “I am extremely excited to work alongside the PRECOS team of expert scientists who are leading the way in providing robust models to enable testing of the next generation of oncology drug candidates.”